TOFIDENCE Gains FDA Approval for Cytokine Release Syndrome: Biosimilar Covers CAR-T Complication

The FDA on Wednesday cleared expanded indications for TOFIDENCE (tocilizumab-bavi), Organon's intravenous biosimilar of ACTEMRA, to include cytokine release syndrome in adults and children as young as two years, and COVID-19 in hospitalized pediatric patients — bringing the drug's approved uses in the United States into full alignment with its reference product for the first time since its 2023 launch. For the oncology centers and hospital pharmacies now running CAR-T cell therapy programs, the approval means a biosimilar-priced option for treating one of the deadliest complications of immunotherapy now has the regulatory coverage to enter formularies without restriction.

CRS: Why IL-6 Blockade Became a Lifeline for CAR-T Patients

Cytokine release syndrome is a medical emergency that arises when engineered immune cells do their job too well. When CAR-T cells find their tumor targets and multiply rapidly, the resulting immune activation triggers cascading releases of pro-inflammatory signaling proteins. IL-6 levels surge most dramatically and become the primary driver of the immune storm's most dangerous features — the vascular leakage, hypotension, and multi-organ stress that can follow. Published data from systematic reviews of CAR-T cohorts in diffuse large B-cell lymphoma find that CRS occurs in roughly 67% of treated patients; severe or life-threatening cases requiring ICU-level management occur in a meaningful fraction, and tocilizumab has become the standard first-line pharmacological intervention when CRS escalates.

TOFIDENCE works by the same molecular mechanism as ACTEMRA: it is a recombinant humanized IgG1 monoclonal antibody that binds to both the membrane-bound and soluble forms of the interleukin-6 receptor (mIL-6R and sIL-6R), blocking IL-6 from triggering the downstream STAT3 signaling cascade and the gp130 co-receptor activation pathway that amplifies the inflammatory cascade. Because IL-6 can signal through either receptor form, drugs that block only one pathway provide incomplete coverage; the dual-binding mechanism of tocilizumab is the molecular reason it became the de facto standard of care for severe CRS rather than anti-IL-1 or corticosteroid-only approaches.

How Biosimilar Economics Work — and What They Change for Hospital Formularies

TOFIDENCE reached U.S. pharmacies by a different route than ACTEMRA. Rather than undergoing full de novo clinical development, it was approved through the Biologics Price Competition and Innovation Act's abbreviated pathway — a framework that allows a biosimilar applicant to demonstrate "highly similar" structural, functional, pharmacokinetic, and immunogenicity profiles relative to the reference product without repeating the full Phase III clinical development program from scratch. The approval relied on a comprehensive analytical, non-clinical, and clinical data package submitted to the FDA in September 2022, including a randomized double-blind Phase III study in rheumatoid arthritis patients.

This pathway is economically significant: development costs for a biosimilar are substantially lower than for the originator, and that gap eventually reaches hospital procurement desks as a pricing advantage. For intravenous drugs administered in institutional settings like CRS treatment — where hospitals buy directly and administer under supervision — the practical pathway to adoption is formulary committee approval, not pharmacy-level substitution. TOFIDENCE does not carry an "interchangeable" designation, which means prescribers must authorize any switch away from ACTEMRA for individual patients. What the label expansion accomplishes is removing the regulatory gap that previously prevented formulary committees from formally approving TOFIDENCE for CRS indications at all — enabling the competitive dynamic between biosimilars and ACTEMRA to play out in hospital purchasing negotiations.

Pediatric COVID-19: Closing a Coverage Gap

The second new indication — COVID-19 in hospitalized pediatric patients receiving systemic corticosteroids who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation — closes a specific coverage gap. TOFIDENCE already held an adult COVID-19 indication, and tocilizumab's benefit in severe COVID-19 is grounded in the RECOVERY trial and related data establishing that IL-6 receptor blockade reduces mortality in hospitalized adults requiring respiratory support. The same immunopathological process underlies severe pediatric presentations that require intensive intervention.

Extending formal FDA approval of TOFIDENCE to hospitalized pediatric COVID-19 patients ensures that institutions managing critically ill children have access to a biosimilar-priced option with a complete U.S. regulatory package, rather than relying solely on ACTEMRA or extrapolating from adult biosimilar labels.

Tocilizumab Biosimilar Competition Accelerates

TOFIDENCE's new approvals arrive against a backdrop of accelerating competition in the tocilizumab biosimilar market. In August 2025, the FDA approved Avtozma (tocilizumab-anoh) from Celltrion for CRS, bringing that product's intravenous formulation into full alignment with ACTEMRA's U.S. label — making it the first tocilizumab biosimilar to achieve complete label parity. Avtozma launched commercially on August 31, 2025. Wednesday's TOFIDENCE approval completes the same alignment for Organon's product, roughly nine months later.

With at least two fully aligned IV tocilizumab biosimilars now competing alongside ACTEMRA, hospital formulary committees have genuine choice options for CRS treatment protocols. The oncology community has watched biosimilar competition drive down costs in other high-use biologic categories; a competitive IV tocilizumab market could apply similar pressure to one of the most consistently prescribed agents in oncology support care.

Organon, which carved out its independent identity from Merck in 2021 and acquired the U.S. regulatory and commercial rights to TOFIDENCE from Biogen in the second quarter of 2025, has described biosimilars as a key growth driver. The company announced in April 2026 that Sun Pharmaceutical Industries Limited had agreed to acquire Organon in an all-cash transaction expected to close in early 2027. Bio-Thera Solutions Ltd., the original developer of TOFIDENCE, retains U.S. manufacturing rights.

TOFIDENCE is administered as a 60-minute intravenous infusion and is supplied in 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL single-dose vials. Unlike ACTEMRA, it is not available in a subcutaneous formulation.

Frequently Asked Questions

What is cytokine release syndrome and why does it need treatment?

Cytokine release syndrome is an acute, potentially life-threatening inflammatory reaction that occurs when the immune system releases massive quantities of pro-inflammatory proteins called cytokines. In the context of CAR-T cell therapy — now widely used for blood cancers — CRS is among the most common and serious complications, occurring to some degree in a majority of treated patients. Tocilizumab treats it by blocking the IL-6 receptor, which interrupts one of the primary molecular signals driving the immune storm.

Is TOFIDENCE the same as ACTEMRA?

TOFIDENCE and ACTEMRA contain the same active ingredient, tocilizumab, and the FDA has determined that TOFIDENCE is highly similar to ACTEMRA with no clinically meaningful differences in safety, efficacy, or immunogenicity. However, TOFIDENCE is not currently designated as "interchangeable" with ACTEMRA, meaning that a prescriber must authorize any switch — TOFIDENCE cannot be automatically substituted for ACTEMRA at the pharmacy level the way generic small-molecule drugs can.

How does the FDA approve a biosimilar for a new indication?

When a biosimilar sponsor seeks a new indication that the reference product already holds, the FDA can grant approval through a process called "extrapolation" — applying the totality of evidence supporting the reference product's safety and efficacy for that indication, combined with the biosimilar's demonstrated equivalence, without requiring the biosimilar sponsor to repeat the full clinical trial program for that specific indication.

What does this approval mean for hospital formularies?

Hospital formulary committees can now formally consider TOFIDENCE for CRS treatment protocols on equal regulatory footing with ACTEMRA. Because tocilizumab for CRS is administered intravenously in institutional settings, hospitals purchase it directly; the label expansion enables biosimilar inclusion in those purchasing decisions, which creates the conditions for competitive pricing negotiations between biosimilar manufacturers and hospital systems.